Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia selected as partner for major regional health region in Italy

Aiforia Technologies

Translation: Original published in Finnish on 1/27/2025 at 7:21 am EET.

Aiforia announced that he Lombardy region health authorities in Italy have selected the company as their partner for AI-assisted image analysis for clinical diagnostics in pathology. The collaboration covers the use of Aiforia's clinical AI solutions for the analysis of breast, lung and prostate cancer biopsies and Aiforia's AI model development software. Lombardy is the largest metropolitan area and the most populous region in northern Italy, with 10 million inhabitants. The center of the area is Milan.

The commercial value of the collaboration was not disclosed in the press release, but a rough estimate could be around 0.5-1.0 MEUR per year, which is about twice the value of the agreement with the smaller Veneto hospital district, which has about half the population. However, it is possible that Aiforia's software will be used to a lesser extent in Lombardy than in Veneto, and it may also take time to implement if the hospital district first orders and installs sample scanners. In any case, we believe that this is an important customer win for Aiforia, whose revenue potential is significantly higher than estimated above as the use of the software expands. The company said in the fall that several bids were already underway, and the news is not surprising given its track record of winning bids. Our forecasts include continuous customer wins, so the news does not put immediate pressure to change our forecasts.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures2024-10-02

202324e25e
Revenue2.43.45.8
growth-%49.3 %41.2 %71.1 %
EBIT (adj.)-12.9-12.1-11.8
EBIT-% (adj.)-537.1 %-358.4 %-204.4 %
EPS (adj.)-0.50-0.42-0.41
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

I’ve been checking the Siemens Healthineers website to see if there are any mentions. It seems like there are big medical events happening right...
7 minutes ago
by Salvelinus
0
Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a...
12 hours ago
by Verneri Pulkkinen
23
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and...
13 hours ago
by Opa
16
It is certainly possible that deals have also been made below the disclosure threshold. I believe there were a few such deals in H1 as well....
20 hours ago
by Jekkku
5
Well, the latest dip is quite clearly due to Faron (and Optomed). Probably the “retail crowd” got spooked, and many interested in these kinds...
20 hours ago
by JusaVaan
2
Faron is quite an extreme example, as its business seems to be a so-called binary case. It either succeeds or fails; there is no middle ground...
20 hours ago
by Puutaheinää
6
Just as @NanoCapKenobi says. Personally, I don’t invest in these still loss-making biotechs with anything other than a multi-year horizon. The...
20 hours ago
by Vino Pino
9
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.